Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 79

1.

Cannabinoid-1 receptor neutral antagonist reduces binge-like alcohol consumption and alcohol-induced accumbal dopaminergic signaling.

Balla A, Dong B, Shilpa BM, Vemuri K, Makriyannis A, Pandey SC, Sershen H, Suckow RF, Vinod KY.

Neuropharmacology. 2018 Mar 15;131:200-208. doi: 10.1016/j.neuropharm.2017.10.040. Epub 2017 Nov 3.

PMID:
29109060
2.

Corrigendum to "Prodepressant- and anxiogenic-like effects of serotonin-selective, but not noradrenaline-selective, antidepressant agents in mice lacking α2-containing GABAA receptors" [Behav. Brain Res. 332 (2017) 172-179].

Benham RS, Hewage NB, Suckow RF, Engin E, Rudolph U.

Behav Brain Res. 2018 Feb 15;338:186-189. doi: 10.1016/j.bbr.2017.10.006. Epub 2017 Oct 22. No abstract available.

PMID:
29070432
3.

Prodepressant- and anxiogenic-like effects of serotonin-selective, but not noradrenaline-selective, antidepressant agents in mice lacking α2-containing GABAA receptors.

Benham RS, Hewage NB, Suckow RF, Engin E, Rudolph U.

Behav Brain Res. 2017 Aug 14;332:172-179. doi: 10.1016/j.bbr.2017.05.063. Epub 2017 Jun 3. Erratum in: Behav Brain Res. 2018 Feb 15;338:186-189.

4.

Accuracy of Clinician Assessments of Medication Status in the Emergency Setting: A Comparison of Clinician Assessment of Antipsychotic Usage and Plasma Level Determination.

Lopez LV, Shaikh A, Merson J, Greenberg J, Suckow RF, Kane JM.

J Clin Psychopharmacol. 2017 Jun;37(3):310-314. doi: 10.1097/JCP.0000000000000697.

PMID:
28353490
5.

Modulating NMDA Receptor Function with D-Amino Acid Oxidase Inhibitors: Understanding Functional Activity in PCP-Treated Mouse Model.

Sershen H, Hashim A, Dunlop DS, Suckow RF, Cooper TB, Javitt DC.

Neurochem Res. 2016 Feb;41(1-2):398-408. doi: 10.1007/s11064-016-1838-8. Epub 2016 Feb 8.

6.

A pilot in vivo proton magnetic resonance spectroscopy study of amino acid neurotransmitter response to ketamine treatment of major depressive disorder.

Milak MS, Proper CJ, Mulhern ST, Parter AL, Kegeles LS, Ogden RT, Mao X, Rodriguez CI, Oquendo MA, Suckow RF, Cooper TB, Keilp JG, Shungu DC, Mann JJ.

Mol Psychiatry. 2016 Mar;21(3):320-7. doi: 10.1038/mp.2015.83. Epub 2015 Aug 18.

7.

The effect of transient increases in kynurenic acid and quinolinic acid levels early in life on behavior in adulthood: Implications for schizophrenia.

Iaccarino HF, Suckow RF, Xie S, Bucci DJ.

Schizophr Res. 2013 Nov;150(2-3):392-7. doi: 10.1016/j.schres.2013.09.004. Epub 2013 Sep 30.

8.

The impact of NMDA receptor blockade on human working memory-related prefrontal function and connectivity.

Driesen NR, McCarthy G, Bhagwagar Z, Bloch MH, Calhoun VD, D'Souza DC, Gueorguieva R, He G, Leung HC, Ramani R, Anticevic A, Suckow RF, Morgan PT, Krystal JH.

Neuropsychopharmacology. 2013 Dec;38(13):2613-22. doi: 10.1038/npp.2013.170. Epub 2013 Jul 16.

9.

Relationship of resting brain hyperconnectivity and schizophrenia-like symptoms produced by the NMDA receptor antagonist ketamine in humans.

Driesen NR, McCarthy G, Bhagwagar Z, Bloch M, Calhoun V, D'Souza DC, Gueorguieva R, He G, Ramachandran R, Suckow RF, Anticevic A, Morgan PT, Krystal JH.

Mol Psychiatry. 2013 Nov;18(11):1199-204. doi: 10.1038/mp.2012.194. Epub 2013 Jan 22.

10.

Nicotine fails to attenuate ketamine-induced cognitive deficits and negative and positive symptoms in humans: implications for schizophrenia.

D'Souza DC, Ahn K, Bhakta S, Elander J, Singh N, Nadim H, Jatlow P, Suckow RF, Pittman B, Ranganathan M.

Biol Psychiatry. 2012 Nov 1;72(9):785-94. doi: 10.1016/j.biopsych.2012.05.009. Epub 2012 Jun 19.

PMID:
22717030
11.

Exposure to kynurenic acid during adolescence produces memory deficits in adulthood.

Akagbosu CO, Evans GC, Gulick D, Suckow RF, Bucci DJ.

Schizophr Bull. 2012 Jun;38(4):769-78. doi: 10.1093/schbul/sbq151. Epub 2010 Dec 20.

12.

Characterization of the interactive effects of glycine and D-cycloserine in men: further evidence for enhanced NMDA receptor function associated with human alcohol dependence.

Krystal JH, Petrakis IL, Limoncelli D, Nappi SK, Trevisan L, Pittman B, D'Souza DC, Suckow RF.

Neuropsychopharmacology. 2011 Feb;36(3):701-10. doi: 10.1038/npp.2010.203. Epub 2010 Dec 1. Erratum in: Neuropsychopharmacology. 2011 Mar;36(4):911. Suckow, Raymond F [added].

13.

Further evidence for an immediate antidepressant action of intracerebral drug administration in a model of chronic depression.

Lin Y, Suckow RF, Sarfraz Y, Stone EA.

Int J Neuropsychopharmacol. 2011 Jun;14(5):691-6. doi: 10.1017/S1461145710001161. Epub 2010 Sep 29.

PMID:
20875221
14.

Characterization of in vivo pharmacokinetic properties of the dopamine D1 receptor agonist DAR-0100A in nonhuman primates using PET with [11C] NNC112 and [11C] raclopride.

Slifstein M, Suckow RF, Javitch JA, Cooper T, Lieberman J, Abi-Dargham A.

J Cereb Blood Flow Metab. 2011 Jan;31(1):293-304. doi: 10.1038/jcbfm.2010.91. Epub 2010 Jun 23.

15.

High dose D-serine in the treatment of schizophrenia.

Kantrowitz JT, Malhotra AK, Cornblatt B, Silipo G, Balla A, Suckow RF, D'Souza C, Saksa J, Woods SW, Javitt DC.

Schizophr Res. 2010 Aug;121(1-3):125-30. doi: 10.1016/j.schres.2010.05.012. Epub 2010 Jun 11.

16.

Sex-specific effects of chronic fluoxetine treatment on neuroplasticity and pharmacokinetics in mice.

Hodes GE, Hill-Smith TE, Suckow RF, Cooper TB, Lucki I.

J Pharmacol Exp Ther. 2010 Jan;332(1):266-73. doi: 10.1124/jpet.109.158717. Epub 2009 Oct 14.

17.

Clozapine interaction with phosphatidyl inositol 3-kinase (PI3K)/insulin-signaling pathway in Caenorhabditis elegans.

Karmacharya R, Sliwoski GR, Lundy MY, Suckow RF, Cohen BM, Buttner EA.

Neuropsychopharmacology. 2009 Jul;34(8):1968-78. doi: 10.1038/npp.2009.35. Epub 2009 Mar 25.

18.

Transient cerebral hypoperfusion enhances intraarterial carmustine deposition into brain tissue.

Joshi S, Wang M, Etu JJ, Suckow RF, Cooper TB, Feinmark SJ, Bruce JN, Fine RL.

J Neurooncol. 2008 Jan;86(2):123-32. Epub 2007 Jul 17.

PMID:
17634743
19.

Investigation of the phenylalanine hydroxylase gene and tardive dyskinesia.

Richardson MA, Chao HM, Read LL, Clelland JD, Suckow RF.

Am J Med Genet B Neuropsychiatr Genet. 2006 Mar 5;141B(2):195-7.

PMID:
16402341
20.

Multidose risperidone treatment evaluated in a rodent model of tardive dyskinesia.

Gao XM, Cooper T, Suckow RF, Tamminga CA.

Neuropsychopharmacology. 2006 Sep;31(9):1864-8. Epub 2005 Nov 23.

Supplemental Content

Loading ...
Support Center